Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 705

1.

Superior skin cancer classification by the combination of human and artificial intelligence.

Hekler A, Utikal JS, Enk AH, Hauschild A, Weichenthal M, Maron RC, Berking C, Haferkamp S, Klode J, Schadendorf D, Schilling B, Holland-Letz T, Izar B, von Kalle C, Fröhling S, Brinker TJ; Collaborators.

Eur J Cancer. 2019 Sep 10;120:114-121. doi: 10.1016/j.ejca.2019.07.019. [Epub ahead of print]

2.

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.

Jacquelot N, Yamazaki T, Roberti MP, Duong CPM, Andrews MC, Verlingue L, Ferrere G, Becharef S, Vétizou M, Daillère R, Messaoudene M, Enot DP, Stoll G, Ugel S, Marigo I, Foong Ngiow S, Marabelle A, Prevost-Blondel A, Gaudreau PO, Gopalakrishnan V, Eggermont AM, Opolon P, Klein C, Madonna G, Ascierto PA, Sucker A, Schadendorf D, Smyth MJ, Soria JC, Kroemer G, Bronte V, Wargo J, Zitvogel L.

Cell Res. 2019 Sep 3. doi: 10.1038/s41422-019-0224-x. [Epub ahead of print]

PMID:
31481761
3.

The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.

Paschen A, Schadendorf D.

Recent Results Cancer Res. 2020;214:169-187. doi: 10.1007/978-3-030-23765-3_6.

PMID:
31473853
4.

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Schadendorf D.

Eur J Cancer. 2019 Aug 21;119:168-178. doi: 10.1016/j.ejca.2019.07.010. [Epub ahead of print]

PMID:
31445199
5.

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.

Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.

Eur J Cancer. 2019 Aug 19;119:97-106. doi: 10.1016/j.ejca.2019.07.016. [Epub ahead of print]

6.

Clinical and genetic analysis of melanomas arising in acral sites.

Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I.

Eur J Cancer. 2019 Aug 13;119:66-76. doi: 10.1016/j.ejca.2019.07.008. [Epub ahead of print]

PMID:
31419753
7.

Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks.

Maron RC, Weichenthal M, Utikal JS, Hekler A, Berking C, Hauschild A, Enk AH, Haferkamp S, Klode J, Schadendorf D, Jansen P, Holland-Letz T, Schilling B, von Kalle C, Fröhling S, Gaiser MR, Hartmann D, Gesierich A, Kähler KC, Wehkamp U, Karoglan A, Bär C, Brinker TJ; Collabrators.

Eur J Cancer. 2019 Aug 13;119:57-65. doi: 10.1016/j.ejca.2019.06.013. [Epub ahead of print]

8.

Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in Melanoma.

Stoffels I, Jansen P, Petri M, Goerdt L, Brinker TJ, Griewank KG, Poeppel TD, Schadendorf D, Klode J.

JAMA Netw Open. 2019 Aug 2;2(8):e199020. doi: 10.1001/jamanetworkopen.2019.9020.

9.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
10.

Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data.

Sondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, French LE, Berking C, Schilling B, Haferkamp S, Fröhling S, von Kalle C, Brinker TJ.

Eur J Cancer. 2019 Aug 8;119:30-34. doi: 10.1016/j.ejca.2019.07.009. [Epub ahead of print]

11.

Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.

Kanaki T, Stang A, Gutzmer R, Zimmer L, Chorti E, Sucker A, Ugurel S, Hadaschik E, Gräger NS, Satzger I, Schadendorf D, Livingstone E.

Eur J Cancer. 2019 Aug 8;119:18-29. doi: 10.1016/j.ejca.2019.06.011. [Epub ahead of print]

PMID:
31401470
12.

Deep neural networks are superior to dermatologists in melanoma image classification.

Brinker TJ, Hekler A, Enk AH, Berking C, Haferkamp S, Hauschild A, Weichenthal M, Klode J, Schadendorf D, Holland-Letz T, von Kalle C, Fröhling S, Schilling B, Utikal JS.

Eur J Cancer. 2019 Aug 8;119:11-17. doi: 10.1016/j.ejca.2019.05.023. [Epub ahead of print]

13.

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis.

Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, Totzeck M.

JAMA Netw Open. 2019 Aug 2;2(8):e198890. doi: 10.1001/jamanetworkopen.2019.8890.

14.

Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images.

Hekler A, Utikal JS, Enk AH, Solass W, Schmitt M, Klode J, Schadendorf D, Sondermann W, Franklin C, Bestvater F, Flaig MJ, Krahl D, von Kalle C, Fröhling S, Brinker TJ.

Eur J Cancer. 2019 Sep;118:91-96. doi: 10.1016/j.ejca.2019.06.012. Epub 2019 Jul 18.

15.

Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters.

Viehof J, Livingstone E, Loscha E, Stockhammer P, Bankfalvi A, Plönes T, Mardanzai K, Zimmer L, Sucker A, Schadendorf D, Hegedüs B, Aigner C.

Eur J Cardiothorac Surg. 2019 Jul 18. pii: ezz211. doi: 10.1093/ejcts/ezz211. [Epub ahead of print]

PMID:
31321422
16.

Informations- und Hilfsangebote für Melanompatienten: Präferenzielle Unterschiede zwischen Patienten und Ärzten.

Brütting J, Bergmann M, Schadendorf D, Weber C, Tilgen W, Berking C, Meier F; im Auftrag der NVKH.

J Dtsch Dermatol Ges. 2019 Jun;17(6):652-654. doi: 10.1111/ddg.13831_g. No abstract available.

PMID:
31241828
17.

Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.

Vogel FCE, Bordag N, Zügner E, Trajkovic-Arsic M, Chauvistré H, Shannan B, Váraljai R, Horn S, Magnes C, Thomas Siveke J, Schadendorf D, Roesch A.

J Invest Dermatol. 2019 Jun 21. pii: S0022-202X(19)31782-8. doi: 10.1016/j.jid.2019.06.124. [Epub ahead of print]

PMID:
31229500
18.

The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma.

Phung B, Cieśla M, Sanna A, Guzzi N, Beneventi G, Cao Thi Ngoc P, Lauss M, Cabrita R, Cordero E, Bosch A, Rosengren F, Häkkinen J, Griewank K, Paschen A, Harbst K, Olsson H, Ingvar C, Carneiro A, Tsao H, Schadendorf D, Pietras K, Bellodi C, Jönsson G.

Cell Rep. 2019 Jun 18;27(12):3573-3586.e7. doi: 10.1016/j.celrep.2019.05.069.

19.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.

PMID:
31212163
20.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
21.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.

PMID:
31166680
22.

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Zaremba A, Chorti E, Jockenhöfer F, Bolz S, Sirin S, Glas M, Becker JC, Ugurel S, Roesch A, Schadendorf D, Livingstone E, Hagenacker T, Zimmer L.

J Immunother Cancer. 2019 May 29;7(1):141. doi: 10.1186/s40425-019-0626-9.

23.

Pathologist-level classification of histopathological melanoma images with deep neural networks.

Hekler A, Utikal JS, Enk AH, Berking C, Klode J, Schadendorf D, Jansen P, Franklin C, Holland-Letz T, Krahl D, von Kalle C, Fröhling S, Brinker TJ.

Eur J Cancer. 2019 Jul;115:79-83. doi: 10.1016/j.ejca.2019.04.021. Epub 2019 May 23.

24.

An Animal Model of Cutaneous Cyst Development Enables the Identification of Three Quantitative Trait Loci, Including the Homologue of a Human Locus (TRICY1).

Cosgarea I, Koelsch B, Fischer C, Griewank KG, van den Berg L, Kutritz A, Schadendorf D, Kindler-Röhrborn A.

J Invest Dermatol. 2019 Apr 27. pii: S0022-202X(19)31495-2. doi: 10.1016/j.jid.2019.03.1154. [Epub ahead of print] No abstract available.

PMID:
31039361
25.

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators.

BMC Cancer. 2019 Apr 18;19(1):366. doi: 10.1186/s12885-019-5568-6.

26.

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi.

Jansen P, Cosgarea I, Murali R, Möller I, Sucker A, Franklin C, Paschen A, Zaremba A, Brinker TJ, Stoffels I, Schadendorf D, Klode J, Hadaschik E, Griewank KG.

Cancers (Basel). 2019 Apr 16;11(4). pii: E546. doi: 10.3390/cancers11040546.

27.

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.

Ugurel S, Spassova I, Wohlfarth J, Drusio C, Cherouny A, Melior A, Sucker A, Zimmer L, Ritter C, Schadendorf D, Becker JC.

Cancer Immunol Immunother. 2019 Jun;68(6):983-990. doi: 10.1007/s00262-019-02341-9. Epub 2019 Apr 16.

PMID:
30993371
28.

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM.

Cancer Res. 2019 Jun 1;79(11):2947-2961. doi: 10.1158/0008-5472.CAN-19-0040. Epub 2019 Apr 15.

PMID:
30987999
29.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 May;113:47-54. doi: 10.1016/j.ejca.2019.04.001. Epub 2019 Apr 10.

30.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

31.

Reply to E. Hindié and K.R. Hess.

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A.

J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. No abstract available.

PMID:
30939092
32.

Immunotherapy in non-melanoma skin cancer: updates and new perspectives.

Ascierto PA, Schadendorf D.

Drugs Context. 2019 Mar 25;8:212583. doi: 10.7573/dic.212583. eCollection 2019. No abstract available.

33.

Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences.

Brütting J, Bergmann M, Schadendorf D, Weber C, Tilgen W, Berking C, Meier F; NVKH.

J Dtsch Dermatol Ges. 2019 Jun;17(6):652-654. doi: 10.1111/ddg.13831. Epub 2019 Apr 1. No abstract available.

PMID:
30933429
34.

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.

Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27.

PMID:
30928620
35.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A.

Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. No abstract available.

PMID:
30903870
36.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8.

37.

The prognostic value of sentinel lymph nodes on distant metastasis-free survival in patients with high-risk squamous cell carcinoma.

Jansen P, Petri M, Merz SF, Brinker TJ, Schadendorf D, Stang A, Stoffels I, Klode J.

Eur J Cancer. 2019 Apr;111:107-115. doi: 10.1016/j.ejca.2019.02.004. Epub 2019 Mar 5.

PMID:
30849684
38.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J.

J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.

39.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
40.

Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark.

Brinker TJ, Hekler A, Hauschild A, Berking C, Schilling B, Enk AH, Haferkamp S, Karoglan A, von Kalle C, Weichenthal M, Sattler E, Schadendorf D, Gaiser MR, Klode J, Utikal JS.

Eur J Cancer. 2019 Apr;111:30-37. doi: 10.1016/j.ejca.2018.12.016. Epub 2019 Feb 22.

41.

Treatment in metastatic melanoma-time to re-think.

Schadendorf D, Livingstone E, Zimmer L.

Ann Oncol. 2019 Apr 1;30(4):501-503. doi: 10.1093/annonc/mdz050. No abstract available.

PMID:
30768148
42.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A.

Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2.

PMID:
30721788
43.
44.

B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV: Results from the HIV-HEART study.

Reinsch N, Streeck H, Holzendorf V, Schulze C, Neumann T, Brockmeyer NH, Kehrmann J, Schadendorf D, Esser S; HIV HEART Study Group.

Int J Cardiol. 2019 Apr 15;281:127-132. doi: 10.1016/j.ijcard.2019.01.066. Epub 2019 Jan 23.

PMID:
30711264
45.

[Merkel cell carcinoma].

Drusio C, Becker JC, Schadendorf D, Ugurel S.

Hautarzt. 2019 Mar;70(3):215-227. doi: 10.1007/s00105-019-4360-5. German.

PMID:
30701288
46.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
47.

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D.

Lancet Oncol. 2018 Dec;19(12):e720-e725. doi: 10.1016/S1470-2045(18)30596-5. Review.

PMID:
30507438
48.

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial.

Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C, Goff M, Love SB, Mohammed SB, Middleton MR.

Ann Oncol. 2019 Feb 1;30(2):317-324. doi: 10.1093/annonc/mdy500.

49.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514.

PMID:
30422243
50.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455

Supplemental Content

Loading ...
Support Center